Investor relations

History of siRNAgen Therapeutics Corporation

   
2019
  • 08 
    siRNAgen Therapeutics Corporation was established as a subsidiary of Bioneer for the acceleration of the new drug development
  • 07 
    Successful Preclinical Toxicity Test of Candidates for Treatment of Idiopathic Pulmonary Fibrosis
2015
  •  09 
    Licensing-Out Agreement with Yuhan Corp.
    (3 target SAMiRNA™ drug candidates)
  •  07 
    Japan, China Patent registration of SAMiRNA™ Technology
2014
  •  07 
    U.S. Patent registration of SAMiRNA™ Technology
2013
  •  01 
    Korea Patent registration of SAMiRNA™ Technology
2012
  • 06 
    Certification, Innovative Pharmaceutical Company
    (Minister of Korea Health Industry Development Institute)
2005
  •  12 
    BIONEER Corp. KOSDAQ Listed
2002
  • 04 
    Development of RNA Synthesis process & low Materials
2001
  •  09 
    Completion of world's largest capacity
    DNA synthesis center
2000
  • 05 
    World-first development of
    automatic 384-well DNA synthesizer
1996
  •  07 
    Renamed to BIONEER Corporation
1992
  • 09
    First in Korea to develop and supply primers for PCR
  • 08 
    Est. as a Korea Biotech Inc. (1st KRIBB spin-off)